Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Primary Immunodeficiency Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
Primary Immunodeficiency Therapeutics Trends and Forecast
The future of the global primary immunodeficiency therapeutics market looks promising with opportunities in the immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, and gene therapy markets. The global primary immunodeficiency therapeutics market is expected to reach an estimated $11.1 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are increasing primary immunodeficiency disorders awareness, rising genomic research, and on-going advancement in diagnostoc technologies, such as genetic testing, flow cytometry, and next-generation sequencing.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Primary Immunodeficiency Therapeutics by Segment
The study includes a forecast for the global primary immunodeficiency therapeutics by type, disease type, and region.
Primary Immunodeficiency Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:
- Immunoglobulin Replacement Therapy
- Stem Cell/Bone Marrow Transplantation
- Antibiotic Therapy
- Gene Therapy
- Others
Primary Immunodeficiency Therapeutics Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
- Others
Primary Immunodeficiency Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Primary Immunodeficiency Therapeutics Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies primary immunodeficiency therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the primary immunodeficiency therapeutics companies profiled in this report include-
- Pfizer
- CSL Behring
- Grifols
- Abbott
- Adma Biologics
- Astrazeneca
- Baxter
- Bayer
- Biocon
- Bristol-Myers Squibb
Primary Immunodeficiency Therapeutics Market Insights
The publisher forecasts that antibody deficiency will remain the largest segment due to increasing awareness of antibody deficiency and aging population is more susceptible to antibody deficiency.
Within this market, immunoglobulin replacement therapy is expected to remain the largest segment as it helps to improve the immune system function and also reduces the risk of infections in primary immunodeficiency disorders patients.
North America will remain the largest segment due to high prevalence of primary immunodeficiency disorders and availability of reimbursement for primary immunodeficiency disorders therapeutics.
For more information about this report visit https://www.researchandmarkets.com/r/vw3n7l
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
